Retrieve available abstracts of 15 articles: HTML format
Single Articles
April 2025
TANAKA Y, Ono R, Ashiarai M, Sakurai A, et al The evaluation of the impact of NUDT15 variants on thiopurine metabolism in
Japanese children with acute lymphoblastic leukemia.
Cancer Chemother Pharmacol. 2025;95:50. PubMedAbstract available
February 2025
DARSTEIN C, Yoon D, Yang Y, Kapoor S, et al Population pharmacokinetic modeling of asciminib in support of exposure-response
and ethnic sensitivity analyses in patients with chronic myeloid leukemia.
Cancer Chemother Pharmacol. 2025;95:39. PubMedAbstract available
OUERDANI A, Valenzuela B, Treijtel N, Haddish-Berhane N, et al Evaluation of Bruton's Tyrosine Kinase (BTK) inhibition with alternative doses of
ibrutinib in subjects with Chronic Lymphocytic Leukemia (CLL).
Cancer Chemother Pharmacol. 2025;95:38. PubMedAbstract available
CAO A, Guan Y, Wang J, Li X, et al Dose adjustment strategy for high-dose methotrexate-induced toxicities in
pediatric acute lymphoblastic leukemia: based on population PK analysis and
exposure-toxicity relationship.
Cancer Chemother Pharmacol. 2025;95:33. PubMedAbstract available
January 2025
MAHER KR, Shafer D, Schaar D, Bandyopadhyay D, et al A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid
leukemia or myelodysplastic syndrome.
Cancer Chemother Pharmacol. 2025;95:24. PubMedAbstract available
December 2024
MANGOURA SA, Abdel-Raheem MH, Eltyb HA, Molla MS, et al Influence of CYP2C8*3 and ABCG2 C421A genetic polymorphisms on trough
concentration and molecular response of imatinib in Egyptian patients with
chronic myeloid leukemia.
Cancer Chemother Pharmacol. 2024;95:12. PubMedAbstract available
MATSUI M, Yasu T, Makimoto A, Yuza Y, et al Pharmacokinetic analysis of crushed venetoclax tablets combined with azacitizine
for recurrent pediatric acute myeloid leukemia (AML).
Cancer Chemother Pharmacol. 2024;95:1. PubMedAbstract available
September 2024
CHRISTENSEN SR, Jensen CF, Heldrup J, Taylor Z, et al Hypoalbuminemia in children with acute lymphoblastic leukemia: relation to
asparaginase therapy and impact on high dose methotrexate elimination.
Cancer Chemother Pharmacol. 2024 Sep 21. doi: 10.1007/s00280-024-04713. PubMedAbstract available
July 2024
RAHMAYANTI SU, Amalia R, Rusdiana T Systematic review: genetic polymorphisms in the pharmacokinetics of high-dose
methotrexate in pediatric acute lymphoblastic leukemia patients.
Cancer Chemother Pharmacol. 2024 Jul 13. doi: 10.1007/s00280-024-04694. PubMedAbstract available
June 2024
CEREJA-PANTOJA KBC, de Brito Azevedo TC, Vinagre LWMS, de Moraes FCA, et al Alterations in pharmacogenetic genes and their implications for imatinib
resistance in Chronic Myeloid Leukemia patients from an admixed population.
Cancer Chemother Pharmacol. 2024 Jun 18. doi: 10.1007/s00280-024-04689. PubMedAbstract available
GAIETTO A, Panetta JC, Pauley JL, Relling MV, et al Ommaya reservoir use in pediatric ALL and NHL: a review at St. Jude Children's
Research Hospital.
Cancer Chemother Pharmacol. 2024;93:617-625. PubMedAbstract available
May 2024
KOBAYASHI T, Sato H, Miura M, Fukushi Y, et al Overexposure to venetoclax is associated with prolonged-duration of neutropenia
during venetoclax and azacitidine therapy in Japanese patients with acute myeloid
leukemia.
Cancer Chemother Pharmacol. 2024 May 23. doi: 10.1007/s00280-024-04673. PubMedAbstract available
March 2024
DILLI BATCHA JS, Gota V, Matcha S, Raju AP, et al Predictive performance of population pharmacokinetic models of imatinib in
chronic myeloid leukemia patients.
Cancer Chemother Pharmacol. 2024 Mar 5. doi: 10.1007/s00280-024-04644. PubMedAbstract available
QU W, Lu J, Ji Y, He Z, et al Successful use of Palbociclib combined with Venetoclax and Azacitidine in an
adult with refractory/relapsed therapy-related acute myeloid leukemia.
Cancer Chemother Pharmacol. 2024 Mar 2. doi: 10.1007/s00280-024-04642. PubMedAbstract available
February 2024
MARCELLETTI JF, Sikic BI Continuous 72-h infusion of zosuquidar with chemotherapy in patients with newly
diagnosed acute myeloid leukemia stratified for leukemic blast P-glycoprotein
phenotype.
Cancer Chemother Pharmacol. 2024 Feb 26. doi: 10.1007/s00280-024-04656. PubMedAbstract available